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Abstract: In the current era, the antithrombotic treatment of patients with non-ST segment elevation
acute coronary syndrome (NSTE-ACS) includes standard aspirin, and one of the potent P2Y12
inhibitors ticagrelor or prasugrel. The optimal timing of ticagrelor has not been adequately studied,
while prasugrel is only recommended after coronary angiography prior to PCI. The invasive strategy,
including indication and timing of angiography, depends on risk stratification and a mortality benefit
has been shown in selected high-risk NSTE-ACS undergoing early (<24 h) intervention.
Keywords: non-ST segment elevation acute coronary syndrome; antithrombotic treatment; routine
invasive strategy; optimal timing
1. Introduction
The acute treatment of patients diagnosed with non-ST segment elevation acute coronary syndrome
(NSTE-ACS), consists of pharmacological treatment and potential invasive coronary angiography with
subsequent revascularization if necessary. Whereas, in ST-segment elevation myocardial infarction,
characterized by an occluded epicardial coronary artery, primary percutaneous intervention (PCI) as
soon as possible results in improved outcomes, the invasive treatment decision in NSTE-ACS is more
complex. In NSTE-ACS typically angiographically significant stenosis is observed, while the epicardial
flow is maintained. In this review, we focus on antithrombotic treatment strategies (before or at the
time of coronary angiography) and the invasive management in NSTE-ACS.
2. Antithrombotic Pretreatment Strategies
Antithrombotic treatment (ATT) is the cornerstone in NSTE-ACS patients regardless of invasive
management. The choice, combination, timing of initiation and treatment duration, all depend on
patient characteristics, including the ischemic and bleeding risk, as well as on procedural aspects.
Activation of platelet aggregation and the coagulation cascade plays a key role in the initial phase and
evolution of NSTE-ACS. Therefore, platelet inhibition and anticoagulation are important, especially in
those patients undergoing revascularization.
2.1. Oral Antiplatelet Therapy
Aspirin or acetylsalicylic acid (ASA) is the basis of antiplatelet inhibition. The clopidogrel
in unstable angina to prevent recurrent ischemic Events (CURE) trial showed that the addition of
clopidogrel results in improved clinical outcomes [1]. Based on the results of the PLATO (platelet
inhibition and patient outcomes) and TRITON-TIMI 38 (trial to assess improvement in therapeutic
outcomes by optimizing platelet inhibition with prasugrel–thrombolysis in myocardial infarction 38)
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trials, where the superiority of the novel P2Y12 receptor inhibitors has been shown over clopidogrel,
dual antiplatelet treatment (DAPT), including ASA and a potent P2Y12 receptor inhibitor (ticagrelor or
prasugrel), are recommended by current clinical guidelines [2,3].
While ASA is started as soon as possible, the optimal timing of initiation of the P2Y12 receptor
inhibitor is a matter of debate. Pretreatment with P2Y12 inhibition includes a variety of different
scenarios. The P2Y12 inhibitor can be given prehospital (ambulance), at the emergency department or
even in the catheterization laboratory after coronary angiography (CAG), but before PCI. The rationale
for pretreatment in NSTE-ACS is to achieve sufficient platelet inhibition at the time of PCI, avoiding
ischemic complications, such as acute stent thrombosis. Disadvantages are a high bleeding risk in
patients with extensive coronary artery disease with an indication for revascularization by urgent
coronary artery bypass grafting (CABG), or those who turn out to have another diagnosis, such as aortic
dissection. The pretreatment with clopidogrel the Antiplatelet Therapy for Reduction of Myocardial
Damage During Angioplasty (ARMYDA)-5 PRELOAD study randomized 409 patients to receive
600 mg clopidogrel loading dose 4–8 h before PCI or a 600 mg loading dose in the catheterization
laboratory after coronary angiography, but before PCI [4]. In this trial no significant difference in the
30-day incidence of major adverse cardiac events (MACE): A composite of cardiac death, myocardial
infarction, or unplanned target vessel revascularization, between the pretreatment and no pretreatment
groups (8.8% vs. 10.3%; p = 0.72). No increased risk of bleeding or vascular complications with
pretreatment was observed either (5.4% vs. 7.8%; p = 0.42). The main limitation of this study is
the small proportion of patients with NSTE-ACS (only 39% of the study population). Randomized
pretreatment studies with ticagrelor in NSTE-ACS have not been performed. However, in the PLATO
trial, 18,624 patients were pretreated with ticagrelor versus clopidogrel before undergoing coronary
angiography. Ticagrelor reduced the risk of ischemic events as compared to clopidogrel (9.8 vs. 11.7%.
hazard ratio (HR), 0.84; 95% confidence interval [CI], 0.77 to 0.92; p < 0.001) [2]. Prasugrel has been
investigated more frequently than ticagrelor. In the TRITON-TIIMI 38 trial, 13608 patients with
moderate-to-high-risk acute coronary syndromes (ACS) were randomly allocated to prasugrel or
clopidogrel. All patients randomly allocated to prasugrel were given 60 mg after coronary angiography,
when the anatomy was known. This study showed significant reductions in the prasugrel group
in the rates of myocardial infarction (9.7% for clopidogrel vs. 7.4% for prasugrel), urgent target
vessel revascularization (3.7% vs. 2.5%) and stent thrombosis (2.4% vs. 1.1%). In the ACCOAST
trial (ACCOAST—comparison of prasugrel at the time of percutaneous coronary intervention or as
pretreatment at the time of diagnosis in patients with non-st elevation myocardial infarction), patients
were randomized to prasugrel pretreatment or a strategy comparable to TRITON-TIMI 38 [5]. In the
ACCOAST trial, 4033 patients with NSTE-ACS and a positive troponin level scheduled for CAG were
randomized to prasugrel 30 mg before CAG (pretreatment group) or placebo (control group). When
CAG was followed by PCI, an extra 30 mg of prasugrel was added in the pretreatment group at the
time of PCI, while control patients receive the complete 60 mg of prasugrel. No reduction in the
primary endpoint (composite of cardiovascular death, recurrent myocardial infarction, stroke, urgent
revascularization or glycoprotein IIb/IIIa rescue therapy through day 7) was found with pretreatment
of 30 mg prasugrel (HR with pretreatment 1.02; 95% CI, 0.84–1.25; p = 0.81). There was, however,
a significant increase in thrombolysis in myocardial infarction (TIMI) major bleeding, whether or not
related to CABG, at day 7 in the pretreatment group (2.6% vs. 1.4%. HR 1.90; 95% CI 1.19–3.02;
p = 0.006). This trial was prematurely interrupted on recommendation from the data safety monitoring
board when 398 of the 400 intended primary endpoint events had been collected, corresponding to
4033 of the approximately 4100 patients originally planned. The increase in TIMI major bleeding was
irrespective whether the procedure was performed by radial or femoral access [6]. Therefore, there is
inconclusive evidence regarding the optimal timing of P2Y12 inhibition.
With regard to the optimal P2Y12 inhibitor, the two potent P2Y12 inhibitors ticagrelor and
prasugrel were compared head-to-head in the ISAR-REACT 5 trial [7]. In this multicenter, randomized,
open-label trial, 4018 patients with ACS (58.9% were NSTE-ACS) were randomly assigned to ticagrelor
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(180 mg loading dose before coronary angiography) or prasugrel (60 mg loading dose at the time
of PCI). The primary endpoint (a composite of death, myocardial infarction, or stroke at one year)
occurred in 184 of 2012 patients (9.3%) in the ticagrelor group and in 137 of 2006 patients (6.9%) in
the prasugrel group (HR, 1.36; 95% CI, 1.09–1.70; p = 0.006. There was no significant difference in
bleeding. The ISAR-REACT 5 trial results have to be interpreted with caution. Around a third of
patients were not treated with the assigned drug. Furthermore, the incidence of the primary outcome
in ticagrelor-treated patients in ISAR-REACT 5 and PLATO was similar at 9.3% and 9.8%. However,
the comparison of the results of prasugrel-treated patients in ISAR-REACT 5 and TRITON-TIMI 38
study shows a large difference: The incidence of the primary outcome being 6.9% and 9.9%, respectively.
Despite these limitations, this is the only randomised clinical trial comparing these drugs, and further
data is necessary to determine whether prasugrel is the superior P2Y12 inhibitor.
2.2. Current Guideline Recommendation
In the 2015 European Society of Cardiology (ESC) Guidelines for the management of acute coronary
syndromes in patients presenting without persistent ST-segment elevation no recommendation for or
against pretreatment with these agents can be formulated [8]. Prasugrel in whom coronary anatomy is
not known is not recommended.
2.3. Intravenous Antiplatelet Therapy
The P2Y12 inhibitor cangrelor, an i.v. adenosine triphosphate (ATP) analogue that binds reversibly
and with high affinity to the P2Y12 receptor, and has a fast onset and fast offset of action. This might
provide a desirable combination of protection from ischemia without an excessive risk of bleeding.
In the placebo-controlled CHAMPION-PLATFORM (Cangrelor Versus Standard Therapy to Achieve
Optimal Management of Platelet Inhibition) trial, 5362 patients with NSTE-ACS were randomly
assigned to cangrelor or placebo at the time of PCI, followed by 600 mg clopidogrel [9]. No reduction in
the primary endpoint (a composite of death, myocardial infarction, or ischemia-driven revascularization
at 48 h) was found in the cangrelor group, as compared with the placebo group (odds ratio (OR) in the
cangrelor group, 0.87; 95% CI, 0.71–1.07; p = 0.17). In CHAMPION-PHOENIX, 11,145 patients who were
undergoing either urgent or elective PCI and were randomized to a bolus and infusion of cangrelor or
to receive a loading dose of 600 mg or 300 mg of clopidogrel. The rate of the primary efficacy endpoint
(a composite of death, myocardial infarction, ischemia-driven revascularization, or stent thrombosis at
48 h) was 4.7% in the cangrelor group and 5.9% in the clopidogrel group (p = 0.005). Stent thrombosis
occurred in 0.8% of the patients receiving cangrelor and in 1.4% in the clopidogrel group (OR, 0.62;
95% CI, 0.43–0.90; p = 0.01). There was no significant increase in bleeding. With its ability to reduce
ischemic complications of PCI, cangrelor can be implemented in situations in which ADP-receptor
blockade is needed, but a short-acting intravenous agent would be preferred, such as patients waiting
to undergo CABG.
The use of Intravenous glycoprotein (GP) Iib/IIIa inhibitors as pretreatment have been extensively
studied, and attention should be given to the Acute Catheterization and Urgent Intervention Triage
Strategy (ACUITY) timing trial [10]. In this trial, 9207 patients with moderate to high-risk ACS were
randomly assigned to routine GPIIb/IIIa inhibitor treatment (eptifibatide or abciximab) before PCI
or deferred selective use. The primary endpoint (a composite of death, myocardial infarction or
unplanned revascularisation for ischemia) at 30 days occurred in 7.1% in the routine group and 7.9%
in the deferred group (relative risk, 1.12; 95% CI, 0.97–1.20; p = 0.044 for noninferiority; p = 0.13 for
superiority). There was less major bleeding in the deferred group compared to routine administration
at 30 days (4.9% vs. 6.1%; p < 0.001 for non-inferiority; p = 0.009 for superiority). Eptifibatide was
also studied in the EARLY ACS (Early versus Delayed, Provisional Eptifibatide in Acute Coronary
Syndromes) trial [11]. Early administration of this GPIIb/IIIa inhibitor leads to an increased risk of
major bleeding, while ischemic events did not meet statistical significance.
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2.4. Current Guideline Recommendation
Based on these trials, the current ESC guideline states that it is not recommended to administer
GPIIb/IIIa inhibitors in patients in whom coronary anatomy is not known. The use of GPIIb/IIIa is
reserved for the bailout setting with thrombotic complications.
2.5. Anticoagulants During the Acute Phase
In addition to antiplatelet therapy, anticoagulants are proven to be effective in reducing ischemic
events in NSTE-ACS. With regards to the acute phase, the use of anticoagulant therapy is an essential
adjunct to antiplatelet therapy in the acute treatment of ACS, and is limited to treatment during initial
hospitalization and revascularization. In a meta-analysis of 12 trials involving over 17.000 patients,
short-term unfractionated heparin, or low molecular weight heparin halved the risk of myocardial
infarction or death up to 7 days [12]. Based on these trials, in which therapy was started within a
few hours after diagnosis, it is recommended that this therapy is started early. No trials have been
performed investigating the exact timing of anticoagulants. Anticoagulants are generally given until
revascularization or discharge.
2.6. Unfractioned Heparin (UFH) and Low Molecular Weight Heparin (LMWH).
As described above, the use of UFH or LMWH in addition to aspirin has been shown to be
associated with lower short-term ischemic events. UFH is usually weight-adjusted, and monitored
using activated clotting times. LMWH, the most widely used being enoxaparin, is dosed based on the
weight. Based on a more dose-effect relationship that is more predictable, no monitoring is necessary.
UFH has been compared with LMWH, and meta-analyses have shown less ischemic and bleeding
outcomes with the use of LMWH [13,14]. However, although these meta-analyses include patients
with NSTE-ACS, dedicated NSTE-ACS trials are lacking.
2.7. Fondaparinux
Fondaparinux is a synthetic pentasaccharide that reversibly binds to antithrombin. Dosing is not
based on weight, and monitoring is not necessary, and fondaparinux does not lead to heparin-induced
thrombocytopenia. In the (Organisation to Assess Strategies in Acute Ischemic Syndromes) OASIS-5
trial, fondaparinux and enoxaparin were compared. Fondaparinux was non-inferior to enoxaparin,
but halved in hospital major bleeds at follow-up at nine days [15]. Furthermore, there was a significant
mortality benefit at six-month follow-up. This mortality benefit was not reproduced in a large Swedish
registry [16]. Despite the superior safety profile, fondaparinux was associated with more catheter
thrombosis than enoxaparin, requiring the additional administration of UFH at the time of PCI.
2.8. Bivalirudin
Bivalirudin directly binds to thrombin. Bivalirudin has been compared to UFH in the ACUITY
trial [17]. Patients were randomized to UFH/LMWH plus GPIIb/IIIa inhibition, bivalirudin plus
GPIIb/IIIa inhibition or bivalirudin with bailout use GPIIb/IIIa inhibition. In this trial, while ischemic
outcomes were comparable, bivalirudin with bailout use GPIIb/IIIa inhibition resulted in significantly
less bleeding. However, the reduction in bleeding seems to be explained by concomitant GPIIb/IIIa
inhibition. In the MATRIX (minimizing adverse hemorrhagic events by transradial access site
and systemic implementation of angiox) trial, with a more selective GPIIb/IIIa inhibitor use in the
UFH arm, no difference in a combination of ischemic and bleeding outcomes was observed [18].
With regards to individual outcomes, stent thrombosis was increased, and bleeding risk decreased with
bivalirudin. In VALIDATE-SWEDEHEART (Swedish web-system for enhancement and development
of evidence-based care in heart disease evaluated according to recommended therapies) trial, UFH use
was compared with bivalirudin with limited use of GPIIb/IIIa inhibitors [19]. The investigators showed
comparable risks for both ischemia and bleeding when comparing the two drugs.
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2.9. Anticoagulant and Treatment Strategy
Based on the above, in invasively managed patients, UFH is the standard of choice. Bivalirudin
can be used as an alternative to UFH. In conservatively managed patients, fondaparinux is the first,
choice. In case of cross-over from a conservative to an invasive strategy, additional UFH or bivalirudin
is necessary for PCI.
2.10. Current Guideline Recommendation
In the 2015 ESC guideline, UFH and bivalirudin are recommended in NSTE-ACS undergoing PCI,
while fondaparinux (with additional UFH during PCI) is recommended regardless of the treatment
strategy. Enoxaparin is recommended if fondaparinux is not available.
3. Invasive Coronary Angiography and Revascularization
CAG has an important role in NSTE-ACS. It can confirm or rule out (obstructive) coronary artery
disease, and as a consequence, guide antithrombotic therapy. Second, the culprit and non-culprit
lesion(s) can be identified; establishing the indication for coronary revascularization by either PCI
or CABG. Finally, it can assist in prognostication by assessing the patient’s risk on the basis of
coronary anatomy.
Comparable to STEMI, revascularization in selected NSTE-ACS patients improves 1-year
survival [20]. However, different treatment strategies have emerged over the last two decades.
They differ with regard to the decision for invasive management and the timing of invasive
management. The decision for an invasive strategy should carefully weigh the patient risk profile
and coronary angiography/revascularisation-related risk. These include numerous factors, such as
clinical presentation, comorbidities, risk scores, the occurrence of high-risk characteristics specific
for either CABG or PCI, frailty, cognitive status, estimated life expectancy and the complexity of
coronary anatomy.
3.1. Invasive Versus Conservative Treatment
In general, patients admitted with NSTE-ACS undergo either scheduled for routine CAG and
revascularization or a selective (conservative) approach. The routine invasive strategy consists of early
CAG within 24 to 72 h after admission and subsequent PCI or CABG, where appropriate. The selective
invasive or conservative strategy consists of initial pharmacological therapy and only CAG with
additional PCI or CABG if the pharmacological therapy fails and/or (recurrent) ischemia is detected.
Multiple clinical trials have been performed comparing these two treatment strategies, and current
guideline recommendations are mainly based on the following three trials with long-term follow-up.
In the ICTUS (Invasive Versus Conservative Treatment in Unstable Coronary Syndromes) trial
1200 patients with NSTE-ACS, including an elevated cardiac troponin T, were randomly assigned to an
early invasive strategy or to a more conservative (selectively invasive) strategy. No benefit was seen
for the early invasive strategy in terms of death, non-fatal myocardial infarction, or rehospitalization
for anginal symptoms within one year after randomization [21]. The FRISC-II (Fragmin and Fast
Revascularization during Instability in Coronary Artery Disease) investigates 2457 patients with
NSTE-ACS who were randomly allocated to invasive or non-invasive treatment [22]. The composite of
death or myocardial infarction occurred in 127 (10.4%) versus 174 (14.1%) patients (risk ratio (RR) 0.74
[0.60–0.92], p = 0.005). There were also reductions in readmission (451 [37%] vs. 704 [57%]; RR 0.67
[0.62–0.72], p < 0.001), and revascularization after the initial admission (92 [7.5%] vs. 383 [31%]; RR 0.24
[0.20–0.30], p < 0.001). Moreover, the RITA-3 (randomized trial of a conservative treatment strategy
versus an interventional treatment strategy in patients with unstable angina) randomized 1810 patients
with NSTE-ACS to early intervention or conservative treatment [23]. In this study, an invasive approach
was a better strategy, but the difference was mainly driven by a reduction in refractory angina pectoris.
The primary endpoint (a combined rate of death, non-fatal myocardial infarction, or refractory angina
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at four months; and a combined rate of death or non-fatal myocardial infarction at one year) was met
in 86 (9.6%) of 895 patients in the intervention group, compared with 133 (14.5%) of 915 patients in
the conservative group (RR 0.66, 95% CI 0.51–0.85, p = 0.001). While the early benefit of a routine
invasive strategy has, thus, been shown, long-term results are varying. Therefore, Fox et al. performed
a pooled analysis of all randomized studies (FRISC-II, ICTUS and RITA-3) with 5-year outcomes [24].
Over five years, 14.7% (389 of 2,721) of patients randomly allocated to a routine invasive (RI) approach
reach the endpoints cardiovascular death or non-fatal MI versus 17.9% (475 of 2,746) in the selective
invasive (SI), more conservative strategy (HR: 0.81, 95% CI: 0.71–0.93; p = 0.002). The most marked
treatment effect was on myocardial infarction (10.0% RI strategy vs. 12.9% SI strategy), and there were
consistent trends for cardiovascular deaths (HR: 0.83, 95% CI: 0.68–1.01; p = 0.068) and all deaths (HR:
0.90, 95% CI: 0.77–1.05).
There were 2.0% to 3.8% absolute reductions in cardiovascular death or MI in the low- and
intermediate-risk groups and an 11.1% absolute risk reduction in highest-risk patients.
Important in the interpretation of the trials is the revascularization rate in the conservative or
selective invasive treatment arms. In the ICTUS trial, in the early invasive strategy as per protocol,
97% of patients underwent coronary angiography within 48 h and 98% during hospitalization. Coronary
angiography during hospitalization was 96% in both early invasive groups of RITA-3 and FRISC-II,
and by design, was to be performed <72 h from randomization and <7 days from admission for the
index event, respectively. More importantly, coronary angiography during hospitalization in the
non-invasive groups of FRISC-II and RITA-3 was only 7% and 16%, respectively, compared with 53%
of patients in the selective invasive group in ICTUS. Therefore, selective invasive treatment might be
an alternative strategy as long as ischemia detection is performed with a low threshold. This might
explain the results of the ICTUS trial, in which the selective invasive treatment included ischemia
detection before discharge. Furthermore, in the Netherlands, there is a high density of PCI and non-PCI
angiography performing centers facilitating the transfer of unstable patients or patients with a positive
ischemia detection test.
In summary, a routine invasive strategy has benefit consisting of a reduction in recurrent myocardial
infarction or death, with a larger benefit in higher-risk patients.
3.2. Timing of Invasive Treatment
The second decision involves the optimal timing of angiography following the routine invasive
strategy. Different time windows are defined as immediate (within 2 h), early invasive (within 24 h) or
delayed invasive (after 24 h but within 72 h). In the immediate strategy group no randomized clinical
trials have been performed because of very-high-risk criteria identifying patients who need an urgent
invasive approach. These criteria consist of: Hemodynamic instability or cardiogenic shock, refractory
angina pectoris despite medical treatment, cardiac arrest or life-threatening arrhythmias, acute heart
failure and recurrent dynamic ST- or T-wave changes.
In patients with an out-of-hospital cardiac arrest (OHCA), but without ST-segment elevation on
electrocardiography (ECG), the right timing of coronary angiography especially is still unknown [25,26].
Whether these patients should undergo immediate coronary angiography or delayed invasive treatment
after neurological recovery was addressed in the Coronary Angiography after Cardiac Arrest (COACT)
trial. In this multicenter randomized investigator-initiated trial 552 patients with NSTE-ACS and OHCA
were randomly assigned to immediate angiography and delayed angiography [27]. The primary
endpoint was survival at 90 days. At 90 days, no difference was seen in both groups (64.5% vs. 67.2%;
OR, 0.89; 95% CI, 0.62–1.27; p = 0.51)
While a routine invasive approach in NSTE-ACS is recommended by clinical guidelines,
the optimal timing of invasive strategy is still under debate. Multiple trials have compared immediate,
early and delayed invasive treatment strategies, with discrepant results, and all were statistically
underpowered to detect a mortality benefit. This issue was addressed in a meta-analysis of Jobs et al.
which includes all randomized controlled trials comparing an early versus delayed invasive strategy
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and reporting all-cause mortality at least 30 days after in-hospital randomization [28]. The authors
find that in eight trials (a total of 5324 patients) with a median follow-up of 180 days, no significant
mortality reduction was seen in the early invasive group compared with the delayed invasive group
(HR 0.81; 95% CI 0.64–1.03; p = 0.088). However, in a prespecified analysis of patients with elevated
troponin, present diabetes, a GRACE risk score > 140 and older age (>75 years), lower mortality was
seen with an early invasive strategy. Tests for interaction effects were inconclusive. We note that
these meta-analyses are dominated by the largest TIMACS trial, providing the majority of patients for
the meta-analysis. Furthermore, there is a large variety in the definition of early or delayed invasive
strategy between the different trials.
With regard to the GRACE risk score > 140, the randomized clinical TIMACS trial should be
noted [29]. In this landmark trial, the largest RCT to date, 3031 patients with NSTE-ACS were randomly
allocated to early invasive (within 24 h after randomization) or delayed intervention (≥36 h after
randomization). At six months, no difference was seen in the primary outcome (a composite of
death, myocardial infarction, or stroke) in the early-intervention group (9.6%) as compared to the
delayed-intervention group (11.3%), HR in the early-intervention group, 0.85; 95% CI, 0.68–1.06;
p = 0.15). The median time to angiography was 14 h in the early invasive strategy and 50 h in the
delayed invasive group. Prespecified analysis of high-risk patients showed that early intervention
improved the primary outcome in the third of patients who were at highest risk (i.e., GRACE risk score
>140; HR, 0.65; 95% CI, 0.48–0.89). Albeit a positive subgroup in an overall negative trial, this finding
was recently reproduced. In the VERDICT trial (Very Early Versus Deferred Invasive Evaluation
Using Computerized Tomography) 2147 patients with a clinical suspicion of NSTE-ACS were 1:1
randomized to very early invasive coronary angiography (within 12 h of diagnosis) or standard
invasive (within 48–72 h) [30]. The primary endpoint was a combination of all-cause death, non-fatal
recurrent myocardial infarction, hospital admission for refractory myocardial ischemia, or hospital
admission for heart failure. With a median follow-up time of 4.3 years, no difference was seen in
the primary endpoint in the very early group (27.5%) versus the standard group (29.5%), (HR, 0.92;
95% CI, 0.78–1.08. However, the benefit of an early invasive treatment strategy for predefined high-risk
patients (GRACE risk score > 140) was also confirmed in this trial (HR, 0.81; 95% CI, 0.67–1.01; p value
for interaction = 0.023).
3.3. Current Guideline Recommendations
As outlined in Table 1, the ESC recommends CAG within two hours in patients with very-high-risk
criteria. In patients with a rise and/or fall in cardiac troponin, dynamic ST-or T-wave changes and
a GRACE risk score > 140, the guidelines recommend an early invasive strategy. Intermediate risk
criteria mandate a delayed invasive approach (within 72 h).
Table 1. Risk criteria mandating invasive strategy in non-ST segment elevation acute coronary syndrome
(NSTE-ACS). Adapted from the European Society of Cardiology (ESC) guidelines [8].
Very-High-Risk Criteria
Hemodynamic instability or cardiogenic shock
Recurrent or ongoing chest pain refractory to medical treatment
Life-threatening arrhythmias or cardiac arrest
Mechanical complications of MI
Acute heart failure
Recurrent dynamic ST-T wave changes, particularly with intermittent ST-elevation
High-Risk Criteria
Rise or fall in cardiac troponin compatible with MI
Dynamic ST-or T-wave changes (symptomatic or silent)
GRACE score > 140




Renal insufficiency (eGFR < 60 mL/min/1.73 m2




GRACE risk score > 109 and <140
Low-Risk Criteria
Any characteristics not mentioned above
CABG = coronary artery bypass graft; eGFR = estimated glomerular filtration rate; GRACE = Global Registry of
Acute Coronary Events; LVEF = left ventricular ejection fraction; PCI= percutaneo coronary intervention; MI =
myocardial infarction.
3.4. Summary and Clinical Perspective
In Table 2, the key points in antithrombotic treatment and invasive approach in NSTE-ACS
patients are outlined.
Table 2. Key points in antithrombotic pretreatment and invasive strategies in NSTE-ACS.
Key Points in Antiplatelet Therapy
Aspirin still remains the cornerstone
DAPT with a potent P2Y12 inhibitor is recommended
Pretreatment with P2Y12 inhibitors have no benefits on MACE
Key Points in Anticoagulant Therapy
Anticoagulation should be started at diagnosis
UFH is the first-line therapy
Fondaparinux is the first-line therapy with a selective invasive or conservative management
Key Points in Invasive Coronary Angiography and Revascularization
Routine invasive strategy is recommended by clinical guidelines
An early invasive strategy in patients with high-risk criteria is recommended
DAPT = dual antiplatelet therapy; MACE = major adverse cardiovascular events (a composite endpoint
of cardiovascular death, recurrent myocardial infarction, stroke, urgent revascularization); UFH =
unfractionated heparin.
With the introduction of clopidogrel and the potent P2Y12 inhibitors ticagrelor and prasugrel,
patients benefit from significant reductions in cardiovascular mortality and recurrent myocardial
infarction when added to aspirin, the cornerstone of ACS treatment. Strategies in combining
antithrombotic treatments will be the focus in future research where ischemic benefit should outweigh
the risk of (major) bleeding. While waiting for these trials, an invasive evaluation of coronary anatomy
should be a mandatory part of the treatment strategy in high-risk patients presenting with NSTE-ACS.
Author Contributions: C.C. and P.D. drafted the manuscript. C.C. and P.D. reviewed and edited the final
manuscript. All authors agreed with the final version of the manuscript.
Funding: This research received no external funding.
Conflicts of Interest: P.D. has received research grants from AstraZeneca, consultancy and lecture fees from Royal
Philips/Volcano. C.C. declared no conflict of interest.
J. Clin. Med. 2020, 9, 2578 9 of 10
References
1. Mehta, S.R.; Yusuf, S.; Peters, R.J.; Bertrand, M.E.; Lewis, B.S.; Natarajan, M.K.; Malmberg, K.; Rupprecht, H.-J.;
Zhao, F.; Chrolavicius, S.; et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term
therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001, 358,
527–533. [CrossRef]
2. Wallentin, L.; Becker, R.C.; Budaj, A.; Cannon, C.P.; Emanuelsson, H.; Held, C.; Horrow, J.; Husted, S.;
James, S.; Katus, H.; et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl.
J. Med. 2009, 361, 1045–1057. [CrossRef]
3. Wiviott, S.D.; Braunwald, E.; McCabe, C.H.; Montalescot, G.; Ruzyllo, W.; Gottlieb, S.; Neumann, F.-J.;
Ardissino, D.; De Servi, S.; Murphy, S.A.; et al. Prasugrel versus clopidogrel in patients with acute coronary
syndromes. N. Engl. J. Med. 2007, 357, 2001–2015. [CrossRef] [PubMed]
4. Di Sciascio, G.; Patti, G.; Pasceri, V.; Gatto, L.; Colonna, G.; Montinaro, A. Effectiveness of in-laboratory
high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary
intervention: Results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of Myocardial
Damage during Angioplasty) randomized trial. J. Am. Coll. Cardiol. 2010, 56, 550–557. [CrossRef] [PubMed]
5. Montalescot, G.; Bolognese, L.; Dudek, D.; Goldstein, P.; Hamm, C.; Tanguay, J.-F.; ten Berg, J.M.; Miller, D.L.;
Costigan, T.M.; Goedicke, J.; et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary
syndromes. N. Engl. J. Med. 2013, 369, 999–1010. [CrossRef] [PubMed]
6. Montalescot, G.; Collet, J.-P.; Ecollan, P.; Bolognese, L.; Ten Berg, J.; Dudek, D.; Hamm, C.; Widimsky, P.;
Tanguay, J.-F.; Goldstein, P.; et al. Effect of prasugrel pre-treatment strategy in patients undergoing
percutaneous coronary intervention for NSTEMI: The ACCOAST-PCI study. J. Am. Coll. Cardiol. 2014, 64,
2563–2571. [CrossRef]
7. Schüpke, S.; Neumann, F.-J.; Menichelli, M.; Mayer, K.; Bernlochner, I.; Wöhrle, J.; Richardt, G.; Liebetrau, C.;
Witzenbichler, B.; Antoniucci, D.; et al. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes.
N. Engl. J. Med. 2019, 381, 1524–1534. [CrossRef]
8. Roffi, M.; Patrono, C.; Collet, J.-P.; Mueller, C.; Valgimigli, M.; Andreotti, F.; Bax, J.J.; Borger, M.A.; Brotons, C.;
Chew, D.P.; et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients
presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary
Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of
Cardiology (ESC). Eur. Heart J. 2016, 37, 267–315. [CrossRef]
9. Bhatt, D.L.; Lincoff, A.M.; Gibson, C.M.; Stone, G.W.; McNulty, S.; Montalescot, G.; Kleiman, N.S.;
Goodman, S.G.; White, H.D.; Mahaffey, K.W.; et al. Intravenous platelet blockade with cangrelor during PCI.
N. Engl. J. Med. 2009, 361, 2330–2341. [CrossRef]
10. Stone, G.W.; Bertrand, M.E.; Moses, J.W.; Ohman, E.M.; Lincoff, A.M.; Ware, J.H.; Pocock, S.J.; McLaurin, B.T.;
Cox, D.A.; Jafar, M.Z.; et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa
inhibitors in acute coronary syndromes: The ACUITY Timing trial. JAMA 2007, 297, 591–602. [CrossRef]
11. Giugliano, R.P.; White, J.A.; Bode, C.; Armstrong, P.W.; Montalescot, G.; Lewis, B.S.; van’t Hof, A.; Berdan, L.G.;
Lee, K.L.; Strony, J.T.; et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes.
N. Engl. J. Med. 2009, 360, 2176–2190. [CrossRef] [PubMed]
12. Eikelboom, J.W.; Anand, S.S.; Malmberg, K.; Weitz, J.I.; Ginsberg, J.S.; Yusuf, S. Unfractionated heparin and
low-molecular-weight heparin in acute coronary syndrome without ST elevation: A meta-analysis. Lancet
2000, 355, 1936–1942. [CrossRef]
13. Silvain, J.; Beygui, F.; Barthelemy, O.; Pollack, C., Jr.; Cohen, M.; Zeymer, U.; Huber, K.; Goldstein, P.; Cayla, G.;
Collet, J.P.; et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous
coronary intervention: Systematic review and meta-analysis. BMJ 2012, 344, e553. [CrossRef] [PubMed]
14. Murphy, S.A.; Gibson, C.M.; Morrow, D.A.; Van de Werf, F.; Menown, I.B.; Goodman, S.G.; Mahaffey, K.W.;
Cohen, M.; McCabe, C.H.; Antman, E.M.; et al. Efficacy and safety of the low-molecular weight
heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum:
A meta-analysis. Eur. Heart J. 2007, 28, 2077–2086. [CrossRef]
15. Yusuf, S.; Mehta, S.R.; Chrolavicius, S.; Afzal, R.; Pogue, J.; Granger, C.B.; Budaj, A.; Peters, R.J.; Bassand, J.P.;
Wallentin, L.; et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N. Engl.
J. Med. 2006, 354, 1464–1476. [CrossRef]
J. Clin. Med. 2020, 9, 2578 10 of 10
16. Szummer, K.; Oldgren, J.; Lindhagen, L.; Carrero, J.J.; Evans, M.; Spaak, J.; Edfors, R.; Jacobson, S.H.;
Andell, P.; Wallentin, L.; et al. Association between the use of fondaparinux vs low-molecular-weight heparin
and clinical outcomes in patients with non-ST-segment elevation myocardial infarction. JAMA 2015, 313,
707–716. [CrossRef]
17. Valgimigli, M.; Frigoli, E.; Leonardi, S.; Rothenbühler, M.; Gagnor, A.; Calabrò, P.; Garducci, S.; Rubartelli, P.;
Briguori, C.; Andò, G.; et al. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. N. Engl.
J. Med. 2015, 373, 997–1009. [CrossRef]
18. Valgimigli, M.; Gagnor, A.; Calabró, P.; Frigoli, E.; Leonardi, S.; Zaro, T.; Rubartelli, P.; Briguori, C.; Andò, G.;
Repetto, A.; et al. Radial versus femoral access in patients with acute coronary syndromes undergoing
invasive management: A randomised multicentre trial. Lancet 2015, 385, 2465–2476. [CrossRef]
19. Erlinge, D.; Omerovic, E.; Fröbert, O.; Linder, R.; Danielewicz, M.; Hamid, M.; Swahn, E.; Henareh, L.;
Wagner, H.; Hårdhammar, P.; et al. Bivalirudin versus Heparin Monotherapy in Myocardial Infarction.
N. Engl. J. Med. 2017, 377, 1132–1142. [CrossRef]
20. Stenestrand, U.; Wallentin, L. Early revascularisation and 1-year survival in 14-day survivors of acute
myocardial infarction: A prospective cohort study. Lancet 2002, 359, 1805–1811. [CrossRef]
21. De Winter, R.J.; Windhausen, F.; Cornel, J.H.; Dunselman, P.H.J.M.; Janus, C.L.; Bendermacher, P.E.F.;
Michels, H.R.; Sanders, G.T.; Tijssen, J.G.P.; Verheugt, F.W.A. Early invasive versus selectively invasive
management for acute coronary syndromes. N. Engl. J. Med. 2005, 353, 1095–1104. [CrossRef] [PubMed]
22. Wallentin, L.; Lagerqvist, B.; Husted, S.; Kontny, F.; Ståhle, E.; Swahn, E. Outcome at 1 year after an
invasive compared with a non-invasive strategy in unstable coronary-artery disease: The FRISC II invasive
randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease.
Lancet 2000, 356, 9–16. [CrossRef]
23. Fox, K.A.; Poole-Wilson, P.A.; Henderson, R.A.; Clayton, T.C.; Chamberlain, D.A.; Shaw, T.R.D.; Wheatley, D.L.;
Pocock, S.J. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation
myocardial infarction: The British Heart Foundation RITA 3 randomised trial. Randomized Intervention
Trial of unstable Angina. Lancet 2002, 360, 743–751. [CrossRef]
24. Fox, K.A.; Clayton, T.C.; Damman, P.; Pocock, S.J.; de Winter, R.J.; Tijssen, J.G.P.; Lagerqvist, B.; Wallentin, L.
Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation
acute coronary syndrome a meta-analysis of individual patient data. J. Am. Coll. Cardiol. 2010, 55, 2435–2445.
[CrossRef] [PubMed]
25. Noc, M.; Fajadet, J.; Lassen, J.F.; Kala, P.; MacCarthy, P.; Olivecrona, G.K.; Windecker, S.; Spaulding, C.
Invasive coronary treatment strategies for out-of-hospital cardiac arrest: A consensus statement from the
European association for percutaneous cardiovascular interventions (EAPCI)/stent for life (SFL) groups.
EuroIntervention 2014, 10, 31–37. [CrossRef] [PubMed]
26. Rab, T.; Kern, K.B.; Tamis-Holland, J.E.; Henry, T.D.; McDaniel, M.; Dickert, N.W.; Cigarroa, J.E.; Keadey, M.;
Ramee, S. Cardiac Arrest: A Treatment Algorithm for Emergent Invasive Cardiac Procedures in the
Resuscitated Comatose Patient. J. Am. Coll. Cardiol. 2015, 66, 62–73. [CrossRef]
27. Lemkes, J.S.; Janssens, G.N.; van der Hoeven, N.W.; Jewbali, L.S.D.; Dubois, E.A.; Meuwissen, M.;
Rijpstra, T.A.; Bosker, H.A.; Blans, M.J.; Bleeker, G.B.; et al. Coronary Angiography after Cardiac Arrest
without ST-Segment Elevation. N. Engl. J. Med. 2019, 380, 1397–1407. [CrossRef]
28. Jobs, A.; Mehta, S.R.; Montalescot, G.; Vicaut, E.; Van ‘t Hof, A.W.J.; Badings, E.A.; Neumann, F.-J.; Kastrati, A.;
Sciahbasi, A.; Reuter, P.-G.; et al. Optimal timing of an invasive strategy in patients with non-ST-elevation
acute coronary syndrome: A meta-analysis of randomised trials. Lancet 2017, 390, 737–746. [CrossRef]
29. Mehta, S.R.; Granger, C.B.; Boden, W.E.; Steg, P.G.; Bassand, J.-P.; Faxon, D.P.; Afzal, R.; Chrolavicius, S.;
Jolly, S.S.; Widimsky, P.; et al. Early versus delayed invasive intervention in acute coronary syndromes.
N. Engl. J. Med. 2009, 360, 2165–2175. [CrossRef]
30. Kofoed, K.F.; Kelbæk, H.; Hansen, P.R.; Torp-Pedersen, C.; Hofsten, D.; Klovgaard, L.; Holmvang, L.; Helqvist, S.;
Jorgensen, E.; Galatius, S.; et al. Early Versus Standard Care Invasive Examination and Treatment of Patients
with Non-ST-Segment Elevation Acute Coronary Syndrome. Circulation 2018, 138, 2741–2750. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
